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Abstract 
 
Background 
Indiscriminate usage of injections and lack of safe practices 
during  injection  administration  have  been  reported 
worldwide.  Unnecessary  and  unsafe  injection  usage  not 
only increases the financial burden but are also responsible 
for spreading blood borne diseases including HIV, HBV and 
HCV. To attain a better understanding of the situation of 
injection usage in Bangladesh, a study was conducted at six 
Upazilla  Health  Complexes  (UHCs),  which  are  primary 
healthcare units in Bangladesh. 
Method   
The study involved the retrospective collection of treatment 
sheets of 1048 in-patients at six UHCs from January 2009 to 
June  2009.    The  data  was  then  analyzed  using  statistical 
tests.  
Results 
Among  the  patients  investigated,  60.11%  of  the  patients 
received injections and among them the male population 
received more injection than the female population (males 
vs. females = 62.50% vs. 55.85%). Patients below 12 years of 
age  received  the  highest  proportion  of  injections  and 
highest usage of injections was observed in the month of 
March. The average number of injection(s) prescribed to a 
patient was 2.44 incurring a prescription cost of 280.22 Taka 
(USD  3.92  approx.).  Injections  were  mostly  prescribed  in 
patients  who  were  diagnosed  with  physical  assault  and 
acute  watery  diarrhea  where  intravenous  fluids  and 
antibiotics were most widely prescribed. Non-compliance to 
recapping  of  used  injections  was  very  common  which 
accounted for 22.22% needle stick injuries. 
Conclusion 
The data suggest that indiscriminate and unsafe  injection 
practices  were  occurring  in  all  UHCs.    Such  practices 
resulted in financial losses as well as compromising safety 
for healthcare providers and patients. 
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Background 
The  administration  of  injections  is  a  very  common 
healthcare  procedure.  In  developing  and  transitional 
countries  around  16  thousand  million  injections  are 
administered each year
1 where most of the injections (more 
than 90%) are given for therapeutic purposes while only 5 
to  10%  are  given  for  preventive  measures.  However,  the 
majority of the injections used for therapeutic purposes in 
developing  and  transitional  countries  are  considered 
unnecessary
2. Another factor to be taken into consideration 
is that safe injection administration practices usually do not 
harm  the  recipient;  however,  unsafe  injection 
administration  practices  cause  patients  to  be  exposed  to 
various risks which have caused them major disabilities and 
even death in many cases. 
2, 3  
 
Unsafe injection administration practices have caused more 
than 80,000 deaths a year due to HIV infection alone, and 
have  caused  another  10  million  deaths  due  to  infections 
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involving hepatitis viruses. Collectively such unsafe injection 
administrations practices are causing 1.3 million premature 
deaths per year worldwide, incurring an average treatment 
cost  of  USD  535  million  per  year  due  to  such  infections, 
while the injections itself bear a hidden cost of USD 0.125 
per  injection  in  the  developing  countries
4.    Studies  have 
confirmed  that  there  were  1,495  reported  HIV  cases  in 
Bangladesh until November 2008 and it was estimated that 
another 7,500 persons were living with HIV, which is three 
times the number of HIV  cases reported  since 2003; and 
among  them  11.1%  have  been  associated  with  IV  drug 
abuse
5- 7. 
 
Poor and unsafe injection administration techniques cause 
infections involving hepatitis B virus (HBV), hepatitis C virus 
(HCV), and human immunodeficiency virus (HIV)
 8. In Egypt, 
Pakistan and many other countries it has been confirmed 
that unsafe injection administration techniques alone are an 
important  vector  for  the  introduction  of  HCV  to  a  huge 
number  of  patients.
9-11,  while  in  South  Asia  such 
inappropriate  practices  accounted  for  up  to  9%  of  newly 
acquired  HIV  infections
12.  The  reasons  for  such  unsafe 
injection administration techniques and practices are very 
complex  and  include  structural,  economical  and  socio-
cultural  factors
13.  Moreover,  knowledge  regarding  safe 
practices  of  injection  administration  is  often  very 
suboptimal  among  injection  prescribers,  providers  and 
consumers
14, 15. 
 
The objective of our study was to investigate the pattern of 
injection  usage  in  several  primary  health  care  units  in 
Bangladesh.  The  findings  could  be  a  good  indicator  of 
unsafe  injection  usage  and  could  be  used  to  address  the 
upcoming  threats  of  HIV,  HBV,  and  HCV  infections  in 
Bangladesh. 
 
Method 
Permissions  were  taken  from  all  the  Upazilla  Health  and 
Family  Planning  Officers  (UH&FPO)  Resident  Medical 
Officers  (RMO)  in  charge  of  the  hospitals  and  wards 
respectively. 
 
Study centers 
The study was conducted at six Upazilla Health Complexes 
(UHCs)  in  Dhaka  (Capital  of  Bangladesh).  The  UHCs  were 
located  right  at  the  outskirts  of  Dhaka  city  at  Dhamrai, 
Dohaar, Keranigonj, Savar, Shaturia and Singair. 
 
 
Data Collection 
Retrospective  medication  and  treatment  records  of  30 
patients on an average per month were collected randomly 
from January 2009 to June 2009 at each of the UHCs, except 
Dohaar  UHC,  where  the  records  were  collected  from 
January 2009 to May 2009. Thus from each UHC medication 
records  from  180  in-patients  were  collected  with  the 
exception of Dohaar UHC where medication records of 150 
patients  were  collected.  Interviews  with  the  doctors  and 
nurses  at  each  of  the  UHCs  (with  the  questionnaire 
prepared  by  the  research  team)  and  open  discussion 
sessions were also performed, with the aim to assess their 
perception  on  injection  based  medications  for  disease 
management.  Interviews  were  conducted  on  two  doctors 
and  four  nurses  at  each  UHC.  Open  discussion  sessions 
included two or more doctors from each UHC. 
 
Data analysis process:  
Data were analyzed using Microsoft® Excel 2002 software 
and GraphPad Software 
(http://www.graphpad.com/quickcalcs/ttest1.cfm).] 
 
Results  
Our findings suggest that the male population 62.50% (95% 
CI: 58.26 to 66.56) had received more injections than the 
female population 55.85% (95% CI: 51.56 to 60.06) in all the 
six  UHCs.  It  was  also  found  out  from  the  study  that  the 
highest injection usage of 78.38% (95% CI 62.56 to 88.86) 
was observed in patients whose age was 1 year or lesser. 
Injection usage rate was lower among patients  with ages 
between  5  to  11  years  66.67%  (95%  CI:  52.01  to  78.70), 
while lowest usage was observed in patients aged above 65 
years 43.64% (95% CI: 31.37 to 56.74). The injection usage 
rate was also very low in patients aged between 50 and 65 
years 49.69 % (95% CI: 42.01 to 57.37). Further details are in 
Table – 1.  
 
The  average  injection  usage  rate  as  per  our  study, 
considering  all  the  UHCs,  was  60.11%  (95%  CI:  57.12  to 
63.04), with each patient receiving an average of 2.44  (p 
value  0.0021)  injections.  Seasonal  variations  also  had  an 
impact on the injection usage. In the month of March the 
highest  injection  usage  was  observed  64.16%,  (95%  CI: 
56.77 to 70.93) while lowest injection usages occurred in 
April 53.11% (95%CI: 45.77 to 60.32). However, the number 
of  injections  received  by  each  patient  individually  was 
highest in January 2.73 (p value 0.0141) and lowest in May 
2.24 (p value 0.0026). The study also revealed that 35.24% 
(95%  CI:  31.61  to  39.05)  of  the  patients  received  one 
injection whereas 28.57% (95% CI: 25.18 to 32.22) of them 
received two injections. Most interestingly 5.87% (95% CI: 
4.27 to 8.01) received 6 or more injections. These facts are 
described in greater details in Table – 2.  
 
In our study, it was calculated that “the cost of medication 
in  each  prescription  on  an  average”  was  280.22  Taka 
(Bangladesh National Currency where 1 Taka = 0.014 USD 
approx.) for patients who had injections prescribed to them, 
while  “the  cost  of  injection  based  medications  in  those 
prescriptions” itself were 226.21 Taka, which is 80.73% of 
the  total  cost  of  those  prescriptions.  Interestingly,  it  was 
observed that “the cost of medication in each prescription 
on  average”  for  patients  who  had  not  been  prescribed 
injections was only 79.08 Taka, which is three times lesser 
than that of patients who had been prescribed injections. 
These results are descriptively cited in Table – 4. and Fig-1 
 
Injections  had  been  most  widely  prescribed  in  patients 
suffering physical assaults 23.97% (95% CI: 20.80 to 27.46) 
followed by those patients who were diagnosed with acute 
watery diarrhea and respiratory tract infection where the  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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prescription rates for injections were 17.30% (95% CI: 14.54 
to 20.46) and 11.43% (95% CI: 9.16 to 14.16) respectively. 
Details have been discussed in Table – 5 and Fig – 2. The 
most frequently used category of injections were IV Fluids 
which constituted 26.75% (95% CI: 24.60 to 29.02) of total 
usage  of  injections.  Antibiotics,  NSAIDs  and  antiulcerants 
followed the trail and their percentage usage was 22.66% 
(95% CI: 20.64 to 24.82), 13.44% (95% CI: 11.83 to 15.24) 
and 11.43% (95% CI: 9.93 to 13.12) respectively. Details are 
summarized in Table – 6 and Fig -3.  
 
Interviews with the doctors and the nurses to assess their 
level of awareness with respect to safe injection usage and 
administration  techniques  and  practices  revealed  that 
58.33% (95% CI: 42.18 to 72.88) of them did not wipe the 
site  of  injection  with  rectified  spirit  before  administering 
injections to patients. All of them 100% (95% CI: 88.53 to 
100.00)  reported  that  they  had  used  new  syringes  and 
needles for reconstituting of the medication for injection. It 
was also observed that 72.22% (95% CI: 55.86 to 84.30) of 
the health providers recapped the needles of an injection 
after usage and 22.22% of them (95% CI: 11.47 to 38.33) 
reported  needle  stick  injury  (NSI)  in  the  last  6  months. 
Further detailed figures regarding the matter are presented 
in Table – 7. 
 
Our  study  also  identified  the  underlying  factors  that  had 
influenced  the  healthcare  providers  (Physicians)  to 
prescribe injection(s). 91.67% (95% CI: 62.47 to >99.99) of 
the physicians claimed that they had prescribed injections 
because they had considered the patients’ disease state to 
be very serious.  58.33  %  (95% CI: 31.89 to 80.74) of the 
physicians  believed  that  medications  administered  by 
parenteral routes were more efficacious than administered 
by oral or rectal routes. 66.67% (95% CI: 38.80 to 86.45) of 
them  claimed  that  the  medical  assistants  themselves 
prescribed injections for the patients in the absence of the 
physicians.  Some  physicians  admitted  that  they  had 
prescribed injections to boost their professional image as a 
healthcare  provider.  The  interviewed  physicians  also 
explained  that  the  reasons  behind  such  high  injection 
prescribing  rates  were  also  due  to  the  fact  that  in  many 
cases the patients themselves had demanded for injections, 
and sometimes injections were prescribed as an effort to 
strengthen  litigation  cases  &  compensation  for  physically 
assaulted patients. Please see Table – 8 for more details. 
 
Discussion 
 
Bangladesh is considered to be a developing country with 
more than 75% of the total (142 million) population living in 
rural  areas,  where,  the  basic  needs  of  living  particularly 
health  and  education  remain  largely  unmet;  basic 
healthcare is accessible to lesser than 40% of the population  
16,  17.  The  per  capita  total  expenditure  on  health  in 
Bangladesh is only USD 2.84 compared to USD 30-40 per 
capita, which is the minimum that is required for essential 
health interventions in low income countries 
18.  Rational 
usage of injections is not closely monitored in Bangladesh as 
in  other  developing  regions  of  the  world  and  this 
phenomenon  has  led  to  spread  of  the  deadly  HIV  and 
hepatitis viruses at an alarming rate. 
 
Our study showed that the male population was prescribed 
more injections than the female population, which was in 
contradiction  to  a  study  conducted  in  Cambodia,  which 
revealed  that  women  were  more  likely  to  be  prescribed 
injections than  men and the respective usage rates were 
42%  vs.  28%
19.  A  closer  look  into  the  injection  usages  at 
various  age  groups  demonstrated  that  in  the  age  groups 
“below 1 year” and “5 to 11 years”, the highest percentage 
of injections was used whereas in age groups of 50 years 
and above the least amount of injections was used. These 
findings are worth comparing to a Pakistani study where it 
was reported that 79% of injection receivers were below 5 
years old and 60–76% of the usages occurred in older age 
groups
20. Another study conducted in China reported that 
children,  aged  below  10  years  of  age,  and  the  elderly 
patients, who were 60 years or older, had higher injection 
usage  rates  compared  with  the  young  adults
21.  High 
injection  usage  prevalence  in  age  groups  below  12  years 
may  be  due  to  greater  prevalence  of  respiratory  tract 
infection  and  acute  watery  diarrhea.  Our  study  also 
reported  that  60.11%  of  the  total  patients  under 
investigation at the UHCs were prescribed injections, which 
was lower than injection usage rates of 68% in a Pakistan 
study
20. 
 
In our study it was deduced that the average numbers of 
injections  prescribed  per  patient  were  2.44  which  was 
slightly  lower  than  Indian  studies  that  reported  that  the 
average number of injections prescribed per person were 
2.46, 2.4, 5.1 and 3 during the years 2001,
 2003,
 2004, and 
2005  respectively
14,  22,  15,  23.  According  to  our  study  the 
proportion  of  patients  who  had  received  one  injection 
based medication was 35.24%, while those for patients who 
had been prescribed two Injectables were 28.57%, and only 
5.87%  of  the  investigated  patients  had  been  prescribed 
more than 6 injections. These figures are much lower than 
those reported in the Cambodian study where 40% of the 
patients in the study were prescribed one or more than one 
injection(s) while 18% of them were prescribed five or more 
Injectables 
19. 
 
Total cost of medications in prescriptions, where injections 
had  been  prescribed,  was  280.22  Taka  (3.92  USD);  the 
respective  figures  in  case  of  prescription  that  did  not 
contain injection based medications were only 79.08 Taka 
(1.107 USD). These findings in our study is worth comparing 
with the Pakistani study which reported that the overall cost 
of the prescription was Rs. 95 (USD1.5) when an injection 
was prescribed and was Rs. 44 (USD 0.7) in the absence of 
injections
20.  In  Pakistan  90%  injections  used  were  for 
generalized fever
20, but our study revealed that only 9.84% 
of the injections used were for general weakness and fever. 
However our study revealed that Respiratory Tract Infection 
were  responsible  for  11.43%  of  the  injections  being 
prescribed.  
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in Bangladesh are patients’ demand, belief that injections 
are superior to other routes, marketing efforts by the drug 
manufacturing  companies  and  efforts  to  boost  up  the 
professional  image  of  the  healthcare  providers  (both 
doctors and medical assistant). The most common diagnosis 
for which injections were prescribed was ‘physical assault’. 
The reasons for such high prescription rates of injections in 
assault cases may be due to the complex socio-cultural and 
socio-economic  factors  e.g.  injections  were  prescribed 
according to the seriousness of disease (that is the health 
care  providers  believed  that  injectable  medications  were 
the solution to get prompt action if the patients’ condition 
was  very  serious),  or  injections  were  prescribed  to 
strengthen  litigations  to  compensate  legally  for  physically 
assaulted patients. However, large quantity of intravenous 
fluid usage with no usage of ORS (Oral Re-hydration Solute) 
in the patients diagnosed with ‘acute watery diarrhoea’ in 
our study, surely pointed out irrational practices against the 
WHO guideline
24. In Cambodia, the main reasons stated for 
prescribing injections were severity of the illness (44%) and 
perceived  patient  preferences  for  injectable  medications 
(40%) 
19.  Our  study  demonstrated  that  91.67%  of  the 
injections were based upon solely due to seriousness of the 
disease while 50% of the usage was due to the patients’ 
demand.  This  phenomenon  has  also  been  previously 
reported in other studies e.g. Kermode
25 cited in his findings 
that  health  service  providers  are  influenced  by  popular 
socio-cultural perceptions about injections and professional 
beliefs that injections are better than oral medications. They 
assumed that patients wanted injections, and if an injection 
was not provided during consultation, the patients would 
seek healthcare elsewhere, which meant a loss of status and 
income  on  the  physicians  part.
25  These  can  be  compared 
with our study where 58.33% of the physicians believed that 
injection  medications  were  more  efficacious  than  oral 
dosage forms and another 25% of the physicians mentioned 
that they prescribed injections to boost their professional 
image. Our study also showed that 66.67% of the injection 
prescriptions  were generated by medical assistants  which 
are  in  coherence  with  other  studies  that  showed  that 
around  26%  of  professional  medical  posts  in  rural  areas 
remain vacant and there is high rate of absenteeism (about 
40%)  and  that  treatments  in  the  rural  areas  are  mainly 
(about  45%)  provided  by  unqualified  health  personnel 
including  medical  assistants,  mid-wives,  village  doctors, 
community health workers rather than by qualified medical 
graduates (only 10- 20%)
26. 
 
Our study revealed that 72.22% of the healthcare providers 
had recapped the injection needles after use and 22.22% of 
them  reported  needle  stick  injuries  (NSI)  during  the  6 
months  period  of  our  study  which  is  higher  than  South 
Indian study that showed 17% recapping and 19% NSI 
25. 
However compared to the Cambodian study
19, where 58% 
of  the  respondents  confirmed  that  they  practiced  proper 
recapping  practices  of  injections  while  53%  of  them 
reported NSI, our study had much lower NSI. Nonetheless 
compared to our study NSI are much lower (2.2%) in the 
developed parts of the world
28. The only positive finding in 
our  study  was  that  all  the  healthcare  providers  (100%) 
reported  that  they  were  using  new  syringes  and  new 
needles  each  time  while  injecting  medications  which  is 
better than reports from other studies of 93% in India 
27 and 
97% in China 
29. In our study another vital factor came into 
the focus where it was revealed that more than 50% of the 
healthcare  providers  did  not  wipe  the  injection  site  with 
rectified spirit or any other antiseptics before injecting the 
medication.  This  practice  is  very  important  as  sterilizing 
injection  sites  prior  to  injecting  significantly  lowers  risks 
associated with viral or bacterial infections after injection.
30 
To add to that it was also revealed that more than thirty five 
percent of them did not wash their hands with antiseptics 
lotions or soaps, which further increases risk of infection. All 
these  reports  collectively  indicate  that  unsafe  injection 
usage practices are highly prevalent at the UHCs, which are 
in agreement with the study performed by Simonsen et al. 
which reported that 50% of injections were considered as 
unsafe in 14 of 19 countries
8. 
 
Conclusion 
The  present  study  demonstrated  that  unnecessary  and 
unsafe injection practices are still prevalent in Bangladesh. 
Such practices add more pressure to the financial burdens 
on the government and the general population, moreover it 
threatens public health safety of the whole nation as they 
could be potential  sources to originate and  spread  blood 
borne diseases. Thus immediate governmental intervention 
should  be  taken  to  rationalize  injection  usages  and  train 
healthcare  professionals  about  safe  usage  practices  for 
injections. 
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Figures and Tables 
 
 
 
Usage pattern of injections at various UHCs analyzed by gender 
  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair  Total 
% of male receive 
injection (95% CI 
intervals**) 
75 
(64.15 to 
83.44) 
70.37 
(59.65 to 
79.25) 
32.14 
(23.10 to 
42.75) 
69.07 
(59.27 to 
77.42) 
66.67 
(57.04 to 
75.08) 
61.25 
(50.28 to 
71.19) 
62.50 
(58.26 to 
66.56) 
% of female receive 
injection (95% CI 
intervals**) 
71.56 
(62.44 to 
79.21) 
51.56 
(39.58 to 
63.37) 
38.00 
(29.09 to 
47.80) 
41.24 
(31.95 to 
51.19) 
69.14 
(58.37 to 
78.17) 
65.71 
(54.01 to 
75.78) 
55.85 
(51.56 to 
60.06) 
% Difference between 
male and female(95% CI 
intervals**) 
3 
(0 to 17) 
19* 
(3 to 35) 
- 6 
(- 20 to 0) 
28* 
(14 to 41) 
- 2.5 
(- 16 to 0) 
- 4.5 
(- 20 to 0) 
7* 
(1 to 13) 
p value (Unpaired t-test)  0.6065  0.0204  0.4105  0.0001  0.7244  0.5744  0.0292 
% of cases where injections were prescribed in different age group (95%CI intervals*) 
Age (Year)  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair  Total 
<1 
91.67 
(62.5 to 99.9) 
100.00 
(15.81 to 
100.00) 
42.86 
(15.75 to 
75.02) 
83..33 
(41.78 to 
98.86) 
83.33 
(41.78 to 
98.86) 
75.00 
(28.91 to 
96.59) 
78.38 
(62.56 to 88.86) 
1 to 4 
100 
(38.25 to 100) 
0 
(0 to 83.25) 
44.44 
(18.84 to 
73.37) 
75.00 
(50.03 to 
90.29) 
20.00 
(2.03 to 
64.04) 
25.00 
(3.41 to 
71.09) 
55.26 
(39.70 to 69.86) 
5 to 11 
100 
(65.54 to 100) 
100.00 
(38.25 to 
100.00) 
25.00 
(6.31 to 59.91) 
100.00 
(59.56 to 
100.00) 
46.15 
(23.19 to 
70.87) 
60.00 
(22.91 to 
88.40) 
66.67 
(52.01 to 78.70) 
12 to 19 
80.00 
(54.05 to 93.72 
) 
54.55 
(34.65 to 
73.09) 
56.25 
(33.15 to 
76.93) 
55.00 
(34.19 to 
74.19) 
50.00 
(9.45 to 
90.55) 
71.43 
( 49.79 to 
86.44) 
62.50 
(52.50 to 71.54) 
20 to 34 
70.51 
(59.58 to 
79.52) 
61.76 
(49.86 to 
72.41) 
43.48 
(32.43 to 
55.22) 
56.67 
(44.10 to 
68.43) 
72.73 
(59.68 to 
82.81) 
71.70 
(58.35 to 
82.12) 
62.40 
(57.45 to 67.11) 
35 to 49 
76.67 
(58.80 to 
88.48) 
71.43 
(52.76 to 
84.93) 
36.67 
(21.81 to 
54.55) 
42.00 
(29.36 to 
55.78) 
75.56 
(61.18 to 
85.92) 
62.16 
(46.06 to 
75.98) 
60.00 
(53.41 to 66.25) 
50 to 65  
59.26 
(40.69 to 
75.52) 
60.00 
(40.70 to 
76.64) 
13.79 
(4.88 to 31.18) 
50.00 
(31.43 to 
68.57) 
65.71 
(49.08 to 
79.24) 
47.37 
(27.33 to 
68.30) 
49.69 
(42.01 to 57.37) 
>65 
57.14 
(24.98 to 
84.25) 
50.00 
(67.76 to 
93.24) 
25.00 
(9.71 to 49.97) 
50.00 
(23.66 to 
76.34) 
50.00 
(20.17 to 
79.83) 
50.00 
(18.76 to 
81.24) 
43.64 
(31.37 to 56.74) 
*95% confidence interval calculated by Modified-Wald Method 
Table: 1 - Usage pattern of injections analyzed according to gender and various age groups  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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No. of 
injection 
(s)  per 
patient 
Number of cases of injection usage as per UHCs 
 
Total 
cases 
% 
(Total) 
*CI 
(95%)  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair 
1  40  31  34  33  56  28  222 
35.2
4 
31.61 
to 
39.05 
2  47  25  22  33  32  21  180 
28.5
7 
25.18 
to 
32.22 
3  15  21  5  17  10  23  91 
14.4
4 
11.91 
to 
17.41 
4  10  11  3  19  8  10  61  9.68 
7.60 
to 
12.25 
5  10  5  1  8  8  7  39  6.19 
4.54 
to 
8.37 
6 and 
above  13  2  0  6  10  6  37  5.87 
4.27 
to 
8.01 
 
*95% confidence interval calculated by Modified-Wald Method 
Table – 2: Single and multiple injection usage pattern in six UHCs.  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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Injection use pattern by Geography 
Name of 
UHC  No. of 
patient(s) 
(prescription) 
No. of 
patient(s) 
received 
injection 
% of 
patient(s) 
received 
injection 
CI 
(95%) 
Total 
quantity 
of 
injections 
Average no. 
of injection 
per person 
(prescription) 
p value 
(Unpaired 
t- test ) 
 
95% 
difference 
CI 
 
Dhamrai  185  135  72.97 
66.14 
to 
78.87  359  2.66  0.0051 
13.999 to 
60.668 
Dohaar  152  95  62.50 
54.58 
to 
69.81  217  2.28  0.0027 
11.221 to 
37.579 
Keranigonj  184  65  35.33 
28.62 
to 
42.26  110  1.69  0.1306 
-2.65 to 
17.65 
Savar  194  116  59.79 
52.77 
to 
66.44  309  2.66  0.0001 
21.44 to 
42.89 
Shaturia  183  124  67.76 
60.67 
to 
74.12  295  2.38  0.0003 
16.921 to 
40.079 
Singar  150  95  63.33 
55.37 
to 
70.63  250  2.63  0.0022 
11.78 to 
39.89 
Total  1048  630  60.11 
57.12 
to 
63.04  1540  2.44  0.0021 
69.304 to 
234.029 
Monthly injection use pattern  
 Month 
No. of 
patient(s) 
(prescription) 
Patient(s) 
received 
injection 
% of 
patient(s) 
received 
injection 
CI 
(95%) 
Total 
quantity 
of 
injections 
Average no. 
of injection 
per person 
(prescription) 
p value 
(Unpaired 
t- test ) 
 
95% 
difference 
CI 
 
January  180  103  57.22 
49.92 
to 
64.23  281  2.73  0.0141 
7.394 to 
51.939 
February  176  112  63.64 
56.30 
to 
70.39  262  2.34  0.0335 
2.392 to 
47.608 
March  173  111  64.16 
56.77 
to 
70.93  268  2.41  0.0131 
6.790 to 
45.544 
April  177  94  53.11 
45.77 
to 
60.32  231  2.46  0.0001 
14.75 to 
30.92 
May  184  110  59.78 
52.56 
to 
66.60  246  2.24  0.0026 
9.99 to 
35.35 
June  158  100  63.29 
55.54 
to 
70.41  252  2.52  0.0505 
-0.08 to 
60.88 
Total  1048  630  60.11 
57.12 
to 
63.04  1540  2.44  0.0001 
134.392 
to 
168.942 
Table: 3 – Geographic and Monthly injection usage pattern  
  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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  Total Patients  Patients receiving injection 
Patients not 
receiving injection  Difference Analysis 
Location 
Number 
of 
patients 
Per 
Prescription 
cost 
Number 
of 
patients 
Per 
prescription 
cost 
Per 
Prescription 
cost of 
injection 
(only) 
% cost 
of 
injection 
Number 
of 
patients 
Per 
prescription 
cost 
Difference* 
(CI, 95%) 
% 
difference 
P** 
value 
Dhamrai  185  227.28  135  282.07  220.65  78.22  50  79.34 
203.62 
(145.77 
to 
261.47)  73.98 
0.0001 
 
Dohaar  152  228.44  95  312.60  257.34  82.32  57  88.16 
220.88 
(173.36 
to 
268.40)  71.56 
0.0001 
 
Keranigonj  184  110.54  65  175.87  112.88  64.19  119  74.86 
84.93 
(28.93 
to 
140.92)  52.77 
0.007 
 
Savaar  194  203.64  116  294.40  245.93  83.54  78  68.68 
226.29 
(167.61 
to 
284.97)  76.75 
0.0001 
 
Shaturia  183  223.06  124  289.80  238.22  82.20  59  82.80 
211.03 
(154.42 
to 
267.65)  72.81 
0.0001 
 
Singar  150  214.38  95  286.79  240.77  83.95  55  89.30 
194.24 
(123.95 
to 
264.53)  68.57 
0.0001 
 
All 
Locations  1048  199.99  630  280.22  226.21  80.73  418  79.08 
189.29 
(163.05 
to 
215.52)  70.72 
0.0001 
 
*Statistically significant difference calculated by Paired t - test, **p value calculated by paired t - test 
Table - 4: Cost analysis of injection usage at different UHCs  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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Injection usage in different situations at  different UHCs 
(95% CI*) 
Diagnosis  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair  Total 
Physical Assault 
9.63 
(5.6 to 
15.90) 
63.16 
(53.11 to 
72.18) 
1.54 
(0.01 to 
9.00) 
16.38 
(10.66 to 
24.25) 
25.81 
(18.88 to 
34.19) 
27.37 
(19.37 to 
37.12) 
23.97 
(20.80 to 
27.46) 
Acute Watery 
Diarrhoea 
24.44 
(17.93 to 
32.37) 
9.47 
(4.87 to 
17.23) 
35.38 
(24.85 to 
47.55) 
12.93 
(7.88 to 
20.35) 
14.52 
(9.30 to 
21.87) 
11.58 
(6.43 to 
19.72) 
17.30 
(14.54 to 
20.46) 
Respiratory 
tract infection 
17.04 
(11.57 to 
24.33) 
4.21 
(1.31 to 
1.67) 
6.15 
(1.98 to 
15.22) 
14.66 
(9.26 to 
22.32) 
11.29 
(6.73 to 
18.18) 
10.53 
(5.64 to 
18.48) 
11.43 
(9.16 to 
14.16) 
Acute Abdomen 
with PUD** 
14.81 
(9.72 to 
21.85) 
0 
(0 to 4.66) 
12.31 
(6.11 to 
22.71) 
13.79 
(8.57 to 
21.34) 
13.71 
(8.64 to 
20.96) 
9.47 
(4.87 to 
17.23) 
11.11 
(8.88 to 
13.82) 
General 
weakness and 
fever 
9.63 
(5.6 to 
15.90) 
2.11 
(0.12 to 
7.81) 
6.15 
(1.98 to 
15.22) 
11.21 
(6.54 to 
18.36) 
13.71 
(8.64 to 
20.96) 
13.68 
(8.04 to 
22.15) 
9.84 
(7.74 to 
12.43) 
Full term 
pregnancy with 
labour pain 
10.37 
(6.17 to 
16.77) 
2.11 
(0.12 to 
7.81) 
27.69 
(18.23 to 
39.65) 
5.17 
(2.16 to 
11.06) 
1.61 
(0.08 to 
6.06) 
3.16 
(0.69 to 
9.27) 
7.14 
(5.36 to 
9.44) 
Road Traffic 
Accident 
2.22 
(0.47 to 
6.62) 
10.53 
(5.64 to 
18.48) 
1.54 
(0.01 to 
9.00) 
7.76 
(3.96 to 
14.27) 
4.03 
(1.49 to 
9.34) 
7.37 
(3.38 to 
14.67) 
5.56 
(4.0 to 
7.65) 
Organo 
Phosphate 
Poisoning 
0.74 
(<0.01 to 
4.49) 
0 
(0 to 4.66) 
0 
(0 to 6.68) 
10.34 
(5.88 to 
17.35) 
4.84 
(2.02 to 
10.37) 
5.26 
(1.97 to 
12.03) 
3.81 
(2.55 to 
5.63) 
Others 
11.11 
(6.75 to 
17.63) 
8.42 
(4.11 to 
15.96) 
9.23 
(3.97 to 
19.04) 
7.76 
(3.96 to 
14.27) 
10.48 
(6.11 to 
17.24) 
11.58 
(6.43 to 
19.72) 
9.84 
(7.74 to 
12.43) 
*95% confidence interval calculated by Modified-Wald Method 
**PUD = Peptic Ulcer Disease 
Table – 5: Injection usage in different situations at different UHCs   Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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Therapeutic categories of  injections  prescribed at different UHCs 
(95% CI*) 
Category of  
drugs  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair  Total 
IV fluid 
29.25 
(24.78 to 
34.16) 
27.65 
(22.11 to 
33.96) 
37.27 
(28.80 to 
46.60) 
25.89 
(21.31 to 
31.06) 
30.51 
(25.53 to 
35.99) 
14.40 
(10.55 to 
19.32) 
26.75 
(24.60 to 
29.02) 
Antibiotic 
23.68 
(19.56 to 
28.35) 
21.66 
(16.68 to 
27.63) 
17.27 
(11.26 to 
25.49) 
28.48 
(23.73 to 
33.76) 
14.24 
(10.68 to 
18.71) 
27.20 
(22.05 to 
33.04) 
22.66 
(20.64 to 
24.82) 
NSAID 
6.96 
(4.72 to 
10.12) 
29.49 
(23.81 to 
35.89) 
4.55 
(1.69 to 
10.47) 
7.12 
(4.70 to 
10.59) 
18.98 
(14.90 to 
23.86) 
14.00 
(10.21 to 
18.88) 
13.44 
( 11.83 to 
15.24) 
Antiulcerant 
10.03 
(7.30 to 
13.60) 
12.44 
(8.65 to 
17.54) 
5.45 
(2.28 to 
11.63) 
12.62 
(9.34 to 
16.82) 
11.53 
(8.33 to 
15.71) 
13.60 
(9.86 to 
18.44) 
11.43 
( 9.93 to 
13.12) 
Benzodiaze
pine 
6.13 
(4.04 to 
9.15) 
5.99 
(3.45 to 
10.07) 
3.64 
(1.12 to 
9.28) 
4.85 
(2.90 to 
7.92) 
9.49 
(6.61 to 
13.42) 
8.40 
(5.50 to 
12.56) 
6.69 
(5.54 to 
8.05) 
Antispasmo
dic 
7.52 
(5.18 to 
10.76) 
0.46 
(0.01 to 
2.83) 
5.45 
(2.28 to 
11.63) 
8.41 
(5.77 to 
12.08) 
5.76 
(3.57 to 
9.09) 
8.40 
(5.50 to 
12.56) 
6.36 
( 5.24 to 
7.70) 
Corticostero
id 
4.46 
(2.71 to 
7.17) 
1.38 
(0.28 to 
4.17) 
0.91 
(0.01 to 
5.47) 
5.18 
(3.15 to 
8.30) 
3.73 
(2.02 to 
6.63) 
6.0 
(3.60 to 
9.73) 
4.03 
( 3.15 to 
5.13) 
Antiemetic 
6.41 
(4.27 to 
9.47) 
0 
(0 to 2.09) 
10.91 
(6.21 to 
18.25) 
0.65 
(0.02 to 
2.49) 
1.69 
(0.61 to 
4.02) 
3.20 
( 1.52 to 
6.29) 
3.25 
(2.46 to 
4.26) 
Diuretic 
0.84 
(0.17 to 
2.55) 
0.46 
(0.01 to 
2.83) 
0.91 
(0.01 to 
5.47) 
2.27 
(1.01 to 
4.70) 
3.39 
(1.77 to 
6.21) 
1.60 
( 0.48 to 
4.19) 
1.69 
( 1.14 to 
2.47) 
Labour 
inducer 
1.39 
(0.50 to 
3.31) 
0 
(0 to 2.09) 
12.73 
(7.61 to 
20.36) 
0.65 
(0.02 to 
2.49) 
0 
(0 to 1.55) 
0.4 
(0.01 to 
2.46) 
1.43 
( 0.93 to 
2.17) 
Tetanus 
Toxoid 
0.84 
(0.17 to 
2.55) 
0 
(0 to 2.09) 
0 
(0 to 4.05) 
1.94 
(0.79 to 
4.27) 
0.34 
(0.01 to 
2.09) 
1.20 
( 0.24 to 
3.63) 
0.84 
( 0.48 to 
1.45) 
Others 
2.51 
(1.25 to 
4.77) 
0.46 
(0.01 to 
2.83) 
0.91 
(0.01 to 
5.47) 
1.94 
(0.79 to 
4.27) 
0.34 
(0.01 to 
2.09) 
1.60 
( 0.48 to 
4.19) 
1.43 
( 0.93 to 
2.17) 
*95% confidence interval calculated by Modified-Wald Method 
IV Fluids (includes Normal Saline, 5% Dextrose, 5% Dextrose+0.9% Sodium Chloride, Hartmann Solution, Cholera Saline, 
5%  Amino  Acid);  Antibiotics  (includes  Amoxicillin,  Ampicillin,  Procaine  Penicillin,  Cloxacillin,  Flucloxacillin, 
Ciprofloxacin,  Levofloxacin,  Ceftriaxone,  Cefradine,  Cefuroxime,  Cefotaxime,  Gentamycin,  Metronidazole);  NSAIDs 
(includes Diclofenac Sodium, Ketorolac); Antiulcerants (Ranitidine, Omeprazole, Pentoprazole); Benzodiazepine (includes 
Diazepam);  Antispasmodics  (includes  Tiemonium  methylsulphate,  Hyscine  butyl  bromide,  Atropine  sulphate); 
Corticosteroids (Hydrocortisone, Dexamethasone, Prednisolone); Antiemetics (includes Procholrperazine, Metoclopramide, 
Ondansetron, Domperidone); Diuretics (includes Frusemide); Labour inducer (includes Oxytocin) and Others (includes 
ORS, Vitamin, Iron, Aminophylline, Procyclidine, Cough preparation) 
Table – 6: Distribution of different category of injection drugs at UHCs  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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% of respond among 36 healthcare providers who were interviewed: 2 doctors and 4 nurses from each UHC 
Question  Dhamrai  Dohaar  Keranigonj  Savar  Shaturia  Singair  Total 
Do the health providers wash 
their  hands  with  antiseptic 
soap? (%) 
50.00  (95% 
CI: 18.76 to 
81.24) 
16.67  (95% 
CI:  1.14  to 
58.22) 
16.67  (95% 
CI:  1.14  to 
58.22) 
50.00  (95% 
CI: 18.76 to 
81.24) 
33.33  (95% 
CI:  9.25  to 
70.43) 
50.00  (95% 
CI: 18.76 to 
81.24) 
36.11 
(95%  CI: 
22.42  to 
52.48) 
Do  they  wipe  the  injection 
place  with  rectified  spirit 
before injection? (%) 
66.67  (95% 
CI: 29.57 to 
90.75) 
33.33  (95% 
CI:  9.25  to 
70.43) 
66.67  (95% 
CI: 29.57 to 
90.75) 
83.33  (95% 
CI: 41.78 to 
98.86) 
33.33  (95% 
CI:  9.25  to 
70.43) 
66.67  (95% 
CI: 29.57 to 
90.75) 
58.33 
(95%  CI: 
42.18  to 
72.88) 
Do they prepare the injection 
on a clean table or tray? (%) 
33.33  (95% 
CI:  9.25  to 
70.43) 
0.00  (95%  CI: 
0.00 to 44.28) 
16.67  (95% 
CI:  1.14  to 
58.22) 
16.67  (95% 
CI:  1.14  to 
58.22) 
0.00  (95% 
CI:  0.00  to 
44.28) 
0.00  (95% 
CI:  0.00  to 
44.28) 
11.11 
(95%  CI: 
3.82  to 
25.91) 
Do they use new syringe and 
new  needle  each  time  of 
injection  also  for 
reconstitution  of  medicine? 
(%) 
100.00 
(95%  CI: 
55.72  to 
100.00) 
100.00 (95% 
CI: 55.72 to 
100.00) 
100.00 
(95% CI: 
55.72 to 
100.00) 
100.00 
(95% CI: 
55.72 to 
100.00) 
100.00 
(95% CI: 
55.72 to 
100.00) 
100.00 
(95% CI: 
55.72 to 
100.00) 
100.00 
(95% CI: 
88.53 to 
100.00) 
Do they recap the needle after 
use of injection? 
66.67  (95% 
CI: 29.57 to 
90.75) 
83.33  (95% 
CI:  41.78  to 
98.86) 
83.33  (95% 
CI: 41.78 to 
98.86) 
50.00  (95% 
CI: 18.76 to 
81.24) 
83.33  (95% 
CI: 41.78 to 
98.86) 
66.67  (95% 
CI: 29.57 to 
90.75) 
72.22 
(95%  CI 
55.86  to 
84.30) 
Do  they  report  needle  stick 
injury  in  the  last  6  months? 
(%) 
16.67  (95% 
CI:  1.14  to 
58.22) 
33.33  (95% 
CI:  9.25  to 
70.43) 
33.33  (95% 
CI:  9.25  to 
70.43) 
0.00  (95% 
CI:  0.00  to 
44.28) 
16.67  (95% 
CI:  1.14  to 
58.22) 
33.33  (95% 
CI:  9.25  to 
70.43) 
22.22 
(95%  CI: 
11.47  to 
38.33) 
Are  they  trained  in  injection 
safety practices?  (%) 
66.67  (95% 
CI: 29.57 to 
90.75) 
33.33  (95% 
CI:  9.25  to 
70.43) 
66.67  (95% 
CI: 29.57 to 
90.75) 
83.33  (95% 
CI: 41.78 to 
98.86) 
33.33  (95% 
CI:  9.25  to 
70.43) 
66.67  (95% 
CI: 29.57 to 
90.75) 
58.33 
(95%  CI: 
42.18  to 
72.88) 
Have they completed primary 
hepatitis  B  immunization  (3 
doses)? (%) 
16.67  (95% 
CI:  1.14  to 
58.22) 
0.00  (95%  CI: 
0.00 to 44.28) 
16.67  (95% 
CI:  1.14  to 
58.22) 
33.33  (95% 
CI:  9.25  to 
70.43) 
16.67  (95% 
CI:  1.14  to 
58.22) 
0.00  (95% 
CI:  0.00  to 
44.28) 
13.89 
(95% 
CI:5.61to
29.13) 
*95% confidence interval calculated by Modified-Wald Method 
Table – 7: Indicators for safe use of injection(s) and response of doctors and nurses  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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Factors that influence vigorous injections use  Doctors View  (%) 
Seriousness of the disease  91.67 
(95% CI: 62.47 to >99.99) 
Physical assault for litigation & compensation.  41.67 
(95% CI: 19.26 to 68.11) 
Patients’ demand.  50 
(95% CI: 25.38 to 74.62) 
Doctor’s effort to boost professional image.  25 
(95% CI: 8.27 to 53.85) 
Injection is more efficacious than oral dosage form.  58.33 
(95% CI: 31.89 to 80.74) 
Prescription by medical assistants in absence of the doctors.  66.67 
(95% CI: 38.80 to 86.45) 
Persuasion by Medical Representative of Pharmaceutical Company  16.67 
(95% CI: 3.50 to 46.00) 
 Pressure on doctors to use the medicine stock before expiry date.   8.33 
(95% CI: 0.01 to 37.53) 
*95% confidence interval calculated by Modified-Wald Method 
Table – 8: Factors that influence vigorous injections use by doctors, nurses and others  Australasian Medical Journal AMJ 2011, 4, 1, 26-42 
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